Four venture capital firms have raised more than $1bn in new money for life science and health care investments, which could be divided among a large number of biotechnology companies if a recent trend toward smaller funding rounds continues for US and EU firms.
There's been some concern during the past few record-breaking years of biotech venture capital financing about the decline in seed...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

